Pamela Esposito - 17 Sep 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
17 Sep 2024
Net transactions value
-$329,691
Form type
4
Filing time
17 Sep 2024, 18:20:32 UTC
Previous filing
20 Jun 2024
Next filing
02 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $251,175 +8,500 $29.55 8,500 17 Sep 2024 Direct F1
transaction KYMR Common Stock Options Exercise $70,900 +5,000 +59% $14.18 13,500 17 Sep 2024 Direct F1
transaction KYMR Common Stock Sale $303,185 -6,350 -47% $47.75 7,150 17 Sep 2024 Direct F1, F2
transaction KYMR Common Stock Sale $348,581 -7,150 -100% $48.75 0 17 Sep 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -8,500 -21% $0.000000 31,627 17 Sep 2024 Common Stock 8,500 $29.55 Direct F1, F4
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -5,000 -42% $0.000000 7,000 17 Sep 2024 Common Stock 5,000 $14.18 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.26 to $48.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $49.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The shares underlying this stock option are fully vested and exercisable.